|
|
Risk factors for chronic graft-versus-host disease after anti-thymocyte globulin-based haploidentical hematopoietic stem cell transplantation in acute myeloid leukemia |
Meng Lv1, Xiaohui Zhang1, Lanping Xu1, Yu Wang1, Chenhua Yan1, Huan Chen1, Yuhong Chen1, Wei Han1, Fengrong Wang1, Jingzhi Wang1, Kaiyan Liu1, Xiaojun Huang1,2, Xiaodong Mo1() |
1. Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China 2. Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing 100044, China |
|
|
Abstract Chronic graft-versus-host disease (cGVHD) is a major complication following unmanipulated haploidentical hematopoietic stem cell transplantation (haplo-HSCT). We aimed to identify the risk factors for cGVHD in patients who underwent anti-thymocyte globulin-based haplo-HSCT for acute myeloid leukemia (n=280). The diagnosis of cGVHD was in accordance with the National Institutes of Health consensus criteria. A total of 169 patients suffered from cGVHD. The patients who had 3 loci mismatched had a higher 8-year incidence of cGVHD (total, 66.0% vs. 53.7%, P=0.031; moderate to severe, 42.4% vs. 30.1%, P=0.036) than the patients who had 1 to 2 loci mismatched. The patients who had maternal donors had a higher 8-year incidence of moderate to severe cGVHD (49.2% vs. 32.9%, P=0.024) compared with the patients who had other donors. The patients who had grades III to IV acute GVHD (aGVHD) had higher 8-year incidence of cGVHD (total, 88.0% vs. 50.4%, P<0.001; moderate to severe, 68.0% vs. 27.0%, P<0.001) compared with the patients without aGVHD. In multivariate analysis, grades III to IV aGVHD was the only independent risk factor for cGVHD. Thus, further interventions should be considered in patients with severe aGVHD to prevent cGVHD.
|
Keywords
acute graft-versus-host disease
chronic graft-versus-host disease
National Institutes of Health consensus criteria
acute myeloid leukemia
anti-thymocyte globulin
|
Corresponding Author(s):
Xiaodong Mo
|
Just Accepted Date: 24 July 2019
Online First Date: 23 September 2019
Issue Date: 16 December 2019
|
|
1 |
XJ Huang, HH Zhu, YJ Chang, LP Xu, DH Liu, XH Zhang, B Jiang, Q Jiang, H Jiang, YH Chen, H Chen, W Han, KY Liu, Y Wang. The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission. Blood 2012; 119(23): 5584–5590
https://doi.org/10.1182/blood-2011-11-389809
pmid: 22535659
|
2 |
J Reiffers, AM Stoppa, M Attal, M Michallet, G Marit, D Blaise, F Huguet, B Corront, P Cony-Makhoul, JA Gastaut, G Laurent, L Molina, A Broustet, D Maraninchi, J Pris, D Hollard, C Faberes. Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: the BGMT 87 study. Leukemia 1996; 10(12): 1874–1882
pmid: 8946925
|
3 |
HM Lazarus, WS Pérez, JP Klein, C Kollman, B Bate-Boyle, CN Bredeson, RP Gale, RB Geller, A Keating, MR Litzow, DI Marks, CB Miller, J Douglas Rizzo, TR Spitzer, DJ Weisdorf, MJ Zhang, MM Horowitz. Autotransplantation versus HLA-matched unrelated donor transplantation for acute myeloid leukaemia: a retrospective analysis from the Center for International Blood and Marrow Transplant Research. Br J Haematol 2006; 132(6): 755–769
https://doi.org/10.1111/j.1365-2141.2005.05947.x
pmid: 16487177
|
4 |
M Lv , Y Chang, X Huang. Everyone has a donor: contribution of the Chinese experience to global practice of haploidentical hematopoietic stem cell transplantation. Front Med 2019; 13(1): 45–56
https://doi.org/10.1007/s11684-017-0595-7.
pmid: 29675688
|
5 |
LP Xu, DP Wu, MZ Han, H Huang, QF Liu, DH Liu, ZM Sun, LH Xia, J Chen, HX Wang, C Wang, CF Li, YR Lai, JM Wang, DB Zhou, H Chen, YP Song, T Liu, KY Liu, XJ Huang. A review of hematopoietic cell transplantation in China: data and trends during 2008–2016. Bone Marrow Transplant 2017; 52(11): 1512–1518
https://doi.org/10.1038/bmt.2017.59
pmid: 28436973
|
6 |
L Xu, H Chen, J Chen, M Han, H Huang, Y Lai, D Liu, Q Liu, T Liu, M Jiang, H Ren, Y Song, Z Sun, J Wang, D Wu, D Zhou, P Zou, K Liu, X Huang. The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China-recommendations from the Chinese Society of Hematology. J Hematol Oncol 2018; 11(1): 33
https://doi.org/10.1186/s13045-018-0564-x
pmid: 29495966
|
7 |
Y Wang, QF Liu, LP Xu, KY Liu, XH Zhang, X Ma, ZP Fan, DP Wu, XJ Huang. Haploidentical vs. identical-sibling transplant for AML in remission: a multicenter, prospective study. Blood 2015; 125(25): 3956–3962
https://doi.org/10.1182/blood-2015-02-627786
pmid: 25940714
|
8 |
XD Mo, XH Zhang, LP Xu, Y Wang, CH Yan, H Chen, YH Chen, W Han, FR Wang, JZ Wang, KY Liu, XJ Huang. Unmanipulated haploidentical hematopoietic stem cell transplantation in first complete remission can abrogate the poor outcomes of children with acute myeloid leukemia resistant to the first course of induction chemotherapy. Biol Blood Marrow Transplant 2016; 22(12): 2235–2242
https://doi.org/10.1016/j.bbmt.2016.09.004
pmid: 27614057
|
9 |
XD Mo, LP Xu, XH Zhang, DH Liu, Y Wang, H Chen, CH Yan, YH Chen, W Han, FR Wang, JZ Wang, KY Liu, XJ Huang. Chronic GVHD induced GVL effect after unmanipulated haploidentical hematopoietic SCT for AML and myelodysplastic syndrome. Bone Marrow Transplant 2015; 50(1): 127–133
https://doi.org/10.1038/bmt.2014.223
pmid: 25387095
|
10 |
PL Weiden, KM Sullivan, N Flournoy, R Storb, ED Thomas; Seattle Marrow Transplant Team. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981; 304(25): 1529–1533
https://doi.org/10.1056/NEJM198106183042507
pmid: 7015133
|
11 |
MM Horowitz, RP Gale, PM Sondel, JM Goldman, J Kersey, HJ Kolb, AA Rimm, O Ringdén, C Rozman, B Speck, RT Truitt, FE Zwaan, MM Bortin. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75(3): 555–562
pmid: 2297567
|
12 |
TH Terwey, TM Le Duc, PG Hemmati, P le Coutre, M Nagy, P Martus, B Dörken, R Arnold. NIH-defined graft-versus-host disease and evidence for a potent graft-versus-leukemia effect in patients with acute lymphoblastic leukemia. Ann Oncol 2013; 24(5): 1363–1370
https://doi.org/10.1093/annonc/mds615
pmid: 23247660
|
13 |
C Saillard, R Crocchiolo, S Furst, J El-Cheikh, L Castagna, A Signori, C Oudin, C Faucher, C Lemarie, C Chabannon, A Granata, D Blaise. National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen. Leuk Lymphoma 2014; 55(5): 1106–1112
https://doi.org/10.3109/10428194.2013.820285
pmid: 23822538
|
14 |
D Wolff, A Gerbitz, F Ayuk, A Kiani, GC Hildebrandt, GB Vogelsang, S Elad, A Lawitschka, G Socie, SZ Pavletic, E Holler, H Greinix. Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD. Biol Blood Marrow Transplant 2010; 16(12): 1611–1628
https://doi.org/10.1016/j.bbmt.2010.06.015
pmid: 20601036
|
15 |
YJ Chang, Y Wang, XD Mo, XH Zhang, LP Xu, CH Yan, H Chen, YH Chen, Y Chen, W Han, FR Wang, JZ Wang, KY Liu, XJ Huang. Optimal dose of rabbit thymoglobulin in conditioning regimens for unmanipulated, haploidentical, hematopoietic stem cell transplantation: long-term outcomes of a prospective randomized trial. Cancer 2017; 123(15): 2881–2892
https://doi.org/10.1002/cncr.30540
pmid: 28301690
|
16 |
Y Wang, DH Liu, KY Liu, LP Xu, XH Zhang, W Han, H Chen, YH Chen, XJ Huang. Impact of pretransplantation risk factors on post transplantation outcome of patients with acute myeloid leukemia in remission after haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2013; 19(2): 283–290
https://doi.org/10.1016/j.bbmt.2012.10.002
pmid: 23063629
|
17 |
HJ Kolb, J Mittermüller, C Clemm, E Holler, G Ledderose, G Brehm, M Heim, W Wilmanns. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76(12): 2462–2465
pmid: 2265242
|
18 |
R Storb, RL Prentice, KM Sullivan, HM Shulman, HJ Deeg, KC Doney, CD Buckner, RA Clift, RP Witherspoon, FA Appelbaum, JE Sanders, PS Stewart, ED Thomas. Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. Ann Intern Med 1983; 98(4): 461–466
https://doi.org/10.7326/0003-4819-98-4-461
pmid: 6340576
|
19 |
O Ringdén, T Paulin, B Lönnqvist, B Nilsson. An analysis of factors predisposing to chronic graft-versus-host disease. Exp Hematol 1985; 13(10): 1062–1067
pmid: 2996920
|
20 |
K Atkinson, MM Horowitz, RP Gale, DW van Bekkum, E Gluckman, RA Good, N Jacobsen, HJ Kolb, AA Rimm, O Ringdén, C Rozman, KA Sobocinski, FE Zwaan, MM Bortin. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood 1990; 75(12): 2459–2464
pmid: 2350582
|
21 |
SK Sohn, DH Kim, JH Baek, JG Kim, KB Lee, KH Lee, JH Lee, SJ Choi, JH Lee, IH Shin. Risk-factor analysis for predicting progressive- or quiescent-type chronic graft-versus-host disease in a patient cohort with a history of acute graft-versus-host disease after allogeneic stem cell transplantation. Bone Marrow Transplant 2006; 37(7): 699–708
https://doi.org/10.1038/sj.bmt.1705313
pmid: 16501588
|
22 |
F Yang, D Lu, Y Hu, X Huang, H Huang, J Chen, D Wu, J Wang, C Wang, M Han, H Chen. Risk factors for graft-versus-host disease after transplantation of hematopoietic stem cells from unrelated donors in the China marrow donor program. Ann Transplant 2017; 22: 384–401
https://doi.org/10.12659/AOT.902805
pmid: 28652564
|
23 |
Y Wang, DH Liu, KY Liu, LP Xu, XH Zhang, W Han, H Chen, YH Chen, FR Wang, JZ Wang, YQ Sun, XJ Huang. Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia: nine years of experience at a single center. Cancer 2013; 119(5): 978–985
https://doi.org/10.1002/cncr.27761
pmid: 23097265
|
24 |
CH Yan, DH Liu, KY Liu, LP Xu, YR Liu, H Chen, W Han, Y Wang, YZ Qin, XJ Huang. Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood 2012; 119(14): 3256–3262
https://doi.org/10.1182/blood-2011-09-380386
pmid: 22337715
|
25 |
XJ Huang, DH Liu, KY Liu, LP Xu, H Chen, W Han, YH Chen, JZ Wang, ZY Gao, YC Zhang, Q Jiang, HX Shi, DP Lu. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant 2006; 38(4): 291–297
https://doi.org/10.1038/sj.bmt.1705445
pmid: 16883312
|
26 |
XJ Huang, DH Liu, KY Liu, LP Xu, H Chen, W Han, YH Chen, XH Zhang, DP Lu. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. Biol Blood Marrow Transplant 2009; 15(2): 257–265
https://doi.org/10.1016/j.bbmt.2008.11.025
pmid: 19167686
|
27 |
AH Filipovich, D Weisdorf, S Pavletic, G Socie, JR Wingard, SJ Lee, P Martin, J Chien, D Przepiorka, D Couriel, EW Cowen, P Dinndorf, A Farrell, R Hartzman, J Henslee-Downey, D Jacobsohn, G McDonald, B Mittleman, JD Rizzo, M Robinson, M Schubert, K Schultz, H Shulman, M Turner, G Vogelsang, ME Flowers. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11(12): 945–956
https://doi.org/10.1016/j.bbmt.2005.09.004
pmid: 16338616
|
28 |
ML Slovak, KJ Kopecky, PA Cassileth, DH Harrington, KS Theil, A Mohamed, E Paietta, CL Willman, DR Head, JM Rowe, SJ Forman, FR Appelbaum. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000; 96(13): 4075–4083
pmid: 11110676
|
29 |
ML Sorror, MB Maris, R Storb, F Baron, BM Sandmaier, DG Maloney, B Storer. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106(8): 2912–2919
https://doi.org/10.1182/blood-2005-05-2004
pmid: 15994282
|
30 |
TA Gooley, W Leisenring, J Crowley, BE Storer. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18(6): 695–706
https://doi.org/10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O
pmid: 10204198
|
31 |
S Arai, M Jagasia, B Storer, X Chai, J Pidala, C Cutler, M Arora, DJ Weisdorf, ME Flowers, PJ Martin, J Palmer, D Jacobsohn, SZ Pavletic, GB Vogelsang, SJ Lee. Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. Blood 2011; 118(15): 4242–4249
https://doi.org/10.1182/blood-2011-03-344390
pmid: 21791424
|
32 |
A Ruggeri, Y Sun, M Labopin, A Bacigalupo, F Lorentino, W Arcese, S Santarone, Z Gülbas, D Blaise, G Messina, A Ghavamzadeh, F Malard, B Bruno, JL Diez-Martin, Y Koc, F Ciceri, M Mohty, A Nagler. Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft-versus-host disease prophylaxis in haploidentical transplant. Haematologica 2017; 102(2): 401–410
https://doi.org/10.3324/haematol.2016.151779
pmid: 27758821
|
33 |
A Bashey, MJ Zhang, SR McCurdy, A St Martin, T Argall, C Anasetti, SO Ciurea, O Fasan, S Gaballa, M Hamadani, P Munshi, MM Al Malki, R Nakamura, PV O’Donnell, MA Perales, K Raj, R Romee, S Rowley, V Rocha, RB Salit, M Solh, RJ Soiffer, EJ Fuchs, M Eapen. Mobilized peripheral blood stem cells versus unstimulated bone marrow as a graft source for T-cell-replete haploidentical donor transplantation using post-transplant cyclophosphamide. J Clin Oncol 2017; 35(26): 3002–3009
https://doi.org/10.1200/JCO.2017.72.8428
pmid: 28644773
|
34 |
ME Flowers, Y Inamoto, PA Carpenter, SJ Lee, HP Kiem, EW Petersdorf, SE Pereira, RA Nash, M Mielcarek, ML Fero, EH Warren, JE Sanders, RF Storb, FR Appelbaum, BE Storer, PJ Martin. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood 2011; 117(11): 3214–3219
https://doi.org/10.1182/blood-2010-08-302109
pmid: 21263156
|
35 |
M Grube, E Holler, D Weber, B Holler, W Herr, D Wolff. Risk factors and outcome of chronic graft-versus-host disease after allogeneic stem cell transplantation-results from a single-center observational study. Biol Blood Marrow Transplant 2016; 22(10): 1781–1791
https://doi.org/10.1016/j.bbmt.2016.06.020
pmid: 27343720
|
36 |
M Remberger, G Kumlien, J Aschan, L Barkholt, P Hentschke, P Ljungman, J Mattsson, J Svennilson, O Ringdén. Risk factors for moderate-to-severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2002; 8(12): 674–682
https://doi.org/10.1053/bbmt.2002.v8.abbmt080674
pmid: 12523580
|
37 |
Y Wang, YJ Chang, LP Xu, KY Liu, DH Liu, XH Zhang, H Chen, W Han, YH Chen, FR Wang, JZ Wang, Y Chen, CH Yan, MR Huo, D Li, XJ Huang. Who is the best donor for a related HLA haplotype-mismatched transplant? Blood 2014; 124(6): 843–850
https://doi.org/10.1182/blood-2014-03-563130
pmid: 24916508
|
38 |
S Tamaki, T Ichinohe, K Matsuo, N Hamajima, N Hirabayashi, H Dohy; Japan Society of Hematopoietic Cell Transplantation. Superior survival of blood and marrow stem cell recipients given maternal grafts over recipients given paternal grafts. Bone Marrow Transplant 2001; 28(4): 375–380
https://doi.org/10.1038/sj.bmt.1703146
pmid: 11571510
|
39 |
Y Wang, HX Fu, DH Liu, LP Xu, XH Zhang, YJ Chang, YH Chen, FR Wang, YQ Sun, FF Tang, KY Liu, XJ Huang. Influence of two different doses of antithymocyte globulin in patients with standard-risk disease following haploidentical transplantation: a randomized trial. Bone Marrow Transplant 2014; 49(3): 426–433
https://doi.org/10.1038/bmt.2013.191
pmid: 24292519
|
40 |
YJ Chang, LP Xu, Y Wang, XH Zhang, H Chen, YH Chen, FR Wang, W Han, YQ Sun, CH Yan, FF Tang, XD Mo, KY Liu, XJ Huang. Controlled, randomized, open-label trial of risk-stratified corticosteroid prevention of acute graft-versus-host disease after haploidentical transplantation. J Clin Oncol 2016; 34(16): 1855–1863
https://doi.org/10.1200/JCO.2015.63.8817
pmid: 27091717
|
41 |
YJ Chang, LP Xu, Y Wang, XH Zhang, H Chen, YH Chen, FR Wang, W Han, YQ Sun, CH Yan, FF Tang, XD Mo, KY Liu, XJ Huang. Effects of low-dose glucocorticoid prophylaxis on chronic GVHD and GVHD-free, relapse-free survival after haploidentical transplantation: long-term follow-up of a controlled, randomized open-label trial. Biol Blood Marrow Transplant 2019; 25(3): 529–537
https://doi.org/10.1016/j.bbmt.2018.11.020
pmid: 30481596
|
42 |
XD Mo, YY Zhang, XH Zhang, LP Xu, Y Wang, CH Yan, H Chen, YH Chen, YJ Chang, KY Liu, XJ Huang. The role of collateral related donors in haploidentical hematopoietic stem cell transplantation. Sci Bull (Beijing) 2018; 63(20): 1376–1382
https://doi.org/10.1016/j.scib.2018.08.008
|
43 |
DP Lu, L Dong, T Wu, XJ Huang, MJ Zhang, W Han, H Chen, DH Liu, ZY Gao, YH Chen, LP Xu, YC Zhang, HY Ren, D Li, KY Liu. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 2006; 107(8): 3065–3073
https://doi.org/10.1182/blood-2005-05-2146
pmid: 16380454
|
44 |
MR Huo, XY Pei, D Li, YJ Chang, LP Xu, XH Zhang, KY Liu, XJ Huang. Impact of HLA allele mismatch at HLA-A, -B, -C, -DRB1, and -DQB1 on outcomes in haploidentical stem cell transplantation. Bone Marrow Transplant 2018; 53(5): 600–608
https://doi.org/10.1038/s41409-017-0072-6
pmid: 29335631
|
45 |
F Lorentino, M Labopin, K Fleischhauer, F Ciceri, CR Mueller, A Ruggeri, A Shimoni, M Bornhäuser, A Bacigalupo, Z Gülbas, Y Koc, W Arcese, B Bruno, J Tischer, D Blaise, G Messina, DW Beelen, A Nagler, M Mohty. The impact of HLA matching on outcomes of unmanipulated haploidentical HSCT is modulated by GVHD prophylaxis. Blood Adv 2017; 1(11): 669–680
https://doi.org/10.1182/bloodadvances.2017006429
pmid: 29296709
|
46 |
CA Keever-Taylor, C Bredeson, FR Loberiza, JT Casper, C Lawton, D Rizzo, WH Burns, DA Margolis, DH Vesole, M Horowitz, MJ Zhang, M Juckett, WR Drobyski. Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion. Biol Blood Marrow Transplant 2001; 7(11): 620–630
https://doi.org/10.1053/bbmt.2001.v7.pm11760150
pmid: 11760150
|
47 |
M Kondo, S Kojima, K Horibe, K Kato, T Matsuyama. Risk factors for chronic graft-versus-host disease after allogeneic stem cell transplantation in children. Bone Marrow Transplant 2001; 27(7): 727–730
https://doi.org/10.1038/sj.bmt.1702868
pmid: 11360113
|
48 |
S Carlens, O Ringdén, M Remberger, B Lönnqvist, H Hägglund, S Klaesson, J Mattsson, BM Svahn, J Winiarski, P Ljungman, J Aschan. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. Bone Marrow Transplant 1998; 22(8): 755–761
https://doi.org/10.1038/sj.bmt.1701423
pmid: 9827972
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|